文献速递中枢神经肿瘤放疗姑息放疗与转移瘤放疗物理与技术

放射治疗在实体瘤软脑膜病变管理中的作用

Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.
PubMed 文献 · Adv Radiat Oncol · 2023-09-15

本文综述了放射治疗在实体瘤软脑膜病变(LMD)管理中的证据基础。仅有一项前瞻性随机试验显示质子全脑全脊髓照射(CSI)相比累及野放疗改善了乳腺癌和肺癌患者的中枢神经系统无进展生存,其他多为回顾性研究,缺乏明确生存获益证据。目前最佳管理仍依赖专家意见。

要点

  • 实体瘤LMD的放射治疗证据有限,仅一项前瞻性随机试验评估质子CSI。
  • 质子CSI相比累及野放疗改善了乳腺癌和肺癌患者的中枢神经系统无进展生存。
  • 光子CSI传统上与骨髓和胃肠道毒性增加相关,调强放疗/容积旋转调强放疗可能降低毒性。

核心结论

  • 实体瘤LMD的放射治疗最佳管理仍依赖专家意见。
  • 质子CSI适用于体能状态良好且中枢神经系统外疾病控制良好或有效治疗选择可用的患者。
  • 需要进一步研究以了解放射性核素以及联合鞘内或中枢神经系统穿透性全身治疗的作用。

研究设计与样本

  • 于2022年11月对PubMed进行了全面文献检索,并审查了ClinicalTrials.gov上正在进行的临床试验。
  • 由于高质量已发表证据缺乏,讨论更多基于专家共识和意见,包括对学会指南的审查,而非来自临床试验的证据。

主要发现

  • 仅1项前瞻性随机试验评估了LMD的放射治疗,显示接受质子CSI的乳腺癌和肺癌患者相比累及野放疗,中枢神经系统无进展生存改善。
  • 现代光子CSI技术改善了历史急性血液学毒性发生率,但该模式的总体获益尚未被前瞻性评估。
  • 多项回顾性研究探索了累及野放疗或放疗联合化疗的使用,但缺乏明确的生存获益证据。

临床怎么用

  • 质子CSI适用于体能状态良好且中枢神经系统外疾病控制良好或有效治疗选择可用的患者。
  • 光子CSI传统上与骨髓和胃肠道毒性增加相关,但基于调强放疗/容积旋转调强放疗的光子CSI可能具有降低的毒性特征。
  • 需要进一步研究以了解放射性核素以及联合鞘内或中枢神经系统穿透性全身治疗的作用。

局限性

  • 高质量已发表证据缺乏。
  • 讨论更多基于专家共识和意见,而非来自临床试验的证据。
  • 光子CSI的总体获益尚未被前瞻性评估。
  • 需要进一步研究以了解放射性核素以及联合鞘内或中枢神经系统穿透性全身治疗的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Leptomeningeal disease (LMD) is clinically detected in 5% to 10% of patients with solid tumors and is a source of substantial morbidity and mortality. Prognosis for this entity remains poor and treatments are palliative. Radiation therapy (RT) is an essential tool in the management of LMD, and a recent randomized trial demonstrated a survival benefit for proton craniospinal irradiation (CSI) in select patients. In the setting of this recent advance, we conducted a review of the role of RT in LMD from solid tumors to evaluate the evidence basis for RT recommendations. METHODS AND MATERIALS: In November 2022, we conducted a comprehensive literature search in PubMed, as well as a review of ongoing clinical trials listed on ClinicalTrials.gov, to inform a discussion on the role of RT in solid tumor LMD. Because of the paucity of high-quality published evidence, discussion was informed more by expert consensus and opinion, including a review of societal guidelines, than evidence from clinical trials. RESULTS: Only 1 prospective randomized trial has evaluated RT for LMD, demonstrating improved central nervous system progression-free survival for patients with breast and lung cancer treated with proton CSI compared with involved-field RT. Modern photon CSI techniques have improved upon historical rates of acute hematologic toxicity, but the overall benefit of this modality has not been prospectively evaluated. Multiple retrospective studies have explored the use of involved-field RT or the combination of RT with chemotherapy, but clear evidence of survival benefit is lacking. CONCLUSIONS: Optimal management of LMD with RT remains reliant upon expert opinion, with proton CSI indicated in patients with good performance status and extra-central nervous system disease that is either well-controlled or for which effective treatment options are available. Photon-based CSI traditionally has been associated with increased marrow and gastrointestinal toxicities, though intensity modulated RT/volumetric-modulated arc therapy based photon CSI may have reduced the toxicity profile. Further work is needed to understand the role of radioisotopes as well as combined modality treatment with intrathecal or central nervous system penetrating systemic therapies.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Barbour AB, Kotecha R, Lazarev S, et al. Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors. Adv Radiat Oncol. 2023. PMID: 38405313. doi:10.1016/j.adro.2023.101377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。